Edwards Lifesciences Corporation $EW Stake Lessened by Kornitzer Capital Management Inc. KS

Key Points

• Kornitzer Capital Management cut its stake in Edwards Lifesciences by 18.4% in Q4, selling 22,000 shares and ending the period with 97,560 shares worth about $8.32 million.
• Company insiders have been net sellers recently — including a VP sale of 24,000 shares and a CFO sale of 13,000 shares — with insiders offloading 86,058 shares worth roughly $7.12 million in the last three months (insiders now own 0.31%).
• Edwards posted a quarterly EPS of $0.78 and revenue of $1.65 billion (beats expectations; revenue +16.7% YoY), set FY2026 guidance of $2.95–$3.05 EPS, and carries an average analyst rating of Moderate Buy with a $95.65 price target.

Kornitzer Capital Management Inc. KS cut its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 18.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,560 shares of the medical research company's stock after selling 22,000 shares during the period. Kornitzer Capital Management Inc. KS's holdings in Edwards Lifesciences were worth $8,317,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Edwards Lifesciences by 0.5% in the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company's stock valued at $5,472,147,000 after acquiring an additional 365,581 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 4.9% in the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company's stock valued at $1,617,959,000 after acquiring an additional 977,933 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock valued at $1,478,425,000 after acquiring an additional 1,423,365 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company's stock valued at $1,085,574,000 after acquiring an additional 2,287,783 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company's stock valued at $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 86,058 shares of company stock worth $7,118,636. Corporate insiders own 0.31% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $84.08 on Friday. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $48.47 billion, a price-to-earnings ratio of 44.72, a PEG ratio of 2.10 and a beta of 0.95. The stock's fifty day simple moving average is $82.08 and its 200 day simple moving average is $82.41. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $87.89.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The business had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.60 billion. During the same period in the previous year, the firm posted $0.64 EPS. The company's quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on EW shares. Piper Sandler reiterated an "overweight" rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. TD Cowen upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Friday, January 9th. Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a "hold" rating in a report on Friday, April 24th. Finally, Evercore restated an "outperform" rating and set a $93.00 target price on shares of Edwards Lifesciences in a report on Friday, April 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and an average price target of $95.65.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.